Physician profile
Scott Sneed
NPI 1740281948
$3,611.84
in general payments reported to CMS, 2019-2025
15 companies · $355 in 2025
The $355 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $146 · 2021: $297 · 2022: $929 · 2023: $1,120 · 2024: $433 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,908.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $1,507.95 | 2019-2023 | Iluvien |
| Regeneron Healthcare Solutions, INC. | $784.81 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $351.44 | 2019-2025 | Vabysmo |
| Abbvie INC. | $309.18 | 2022-2025 | Ozurdex |
| Novartis Pharmaceuticals Corporation | $240.22 | 2019-2020 | |
| Allergan, INC. | $150.12 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $85.45 | 2022-2024 | Syfovre |
| Bausch & Lomb Americas INC. | $68.28 | 2022 | |
| Eyepoint US, INC. | $30.63 | 2020-2021 | |
| Astellas Pharma US INC | $23.98 | 2024 | Izervay |
| Ani Pharmaceuticals, INC. | $23.72 | 2025 | Yutiq |
| Biogen, INC. | $20.44 | 2024 | Byooviz |
| Ocular Therapeutix, INC. | $15.62 | 2025 | Dextenza |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Sneed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.